Many are exploring alternatives to traditional ‘per pill’ arrangements underlying reimbursement. This holds implications for pharma manufacturers.
{iframe}https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/innovative-pharma-contracts-when-do-value-based-arrangements-work?cid=other-eml-alt-mip-mck-oth-1710{/iframe}